IP Library Granted Patent US 7,335,799
Granted Patent B2
US 7,335,799 · App. 10/743,470 · Granted Feb 26, 2008

Hydroxyl compounds and compositions for cholesterol management and related uses

Assignee: Esperion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,335,799
App. No.
10/743,470
Granted
Feb 26, 2008
Kind
B2
Abstract

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Claims (34)

1. A compound of the formula I:

or a pharmaceutically acceptable salt, hydrate, solvate or mixture thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 0 to 5;

(b) each occurrence of n is independently an integer ranging from 3 to 7;

(c) X is (CH 2 ) z or Ph, wherein z is an integer from 0 to 4 and Ph is a 1,2-, 1,3-, or 1,4 substituted phenyl group;

(d) each occurrence of R 1 ,R 2 ,R 11 , and R 12 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, phenyl, or benzyl, wherein R 1 ,R 2 ,R 11 , and R 12 are not each simultaneously H; and

(e) each occurrence of Y 1 and Y 2 is independently (C 1 -C 6 )alkyl, OH, COOH, COOR 3 , SO 3 H,

 wherein:

(i) Y 1 and Y 2 are not each simultaneously (C 1 -C 6 )alkyl;

(ii) R 3 is (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C 1 -C 6 )alkoxy, or phenyl groups,

(iii) each occurrence of R 4 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C 2 -C 6 )alkynyl and is unsubstituted or substituted with one or two halo, OH, C 1 -C 6 alkoxy, or phenyl groups; and

(iv) each occurrence of R 5 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C 2 -C 6 )alkynyl.

2. The compound of claim 1 , wherein each occurrence of Y 1 and Y 2 is independently OH, COOR 3 , or COOH.

3. The compound of claim 1 , wherein m is 0.

4. The compound of claim 1 , wherein m is 1.

5. The compound of claim 1 , wherein n is 4.

6. The compound of claim 1 , wherein n is 5.

7. The compound of claim 1 , wherein z is 0.

8. The compound of claim 1 , wherein z is 1.

9. The compound of claim 1 , wherein Y 1 is (C 1 -C 6 )alkyl and Y 2 is OH.

10. The compound of claim 1 , wherein Y 1 is methyl and Y 2 is OH.

11. A compound according to claim 1 wherein said compound has the structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

12. A compound according to claim 1 wherein said compound has the structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

13. A compound according to claim 1 wherein said compound has the structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

14. A compound according to claim 1 wherein said compound has the structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

15. A compound of structure:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

16. A pharmaceutical composition comprising a compound of claim 1 , 15 , 11 , 12 , 13 , or 14 and a pharmaceutically acceptable vehicle, excipient, or diluent.

17. A pharmaceutical composition comprising a compound of claim 1 , 15 , 11 , 12 , 13 , or 14 and further comprising a second therapeutic agent.

18. A pharmaceutical composition comprising a compound of claim 1 , 11 , 12 , 13 , or 14 and a pharmaceutically acceptable vehicle, excipient, or diluent which is administered in combination with a statin.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jul 14, 2026
From: GLAS AMERICAS LLC
To: ESPERION THERAPEUTICS INC.
Reel/Frame 075267/0816 →
PATENT SECURITY AGREEMENT Recorded Jul 13, 2026
From: ESPERION THERAPEUTICS, INC.; RESQ PHARMACEUTICALS LLC
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 075952/0812 →
SECURITY INTEREST Recorded Dec 13, 2024
From: ESPERION THERAPEUTICS, INC.
To: GLAS AMERICAS LLC
Reel/Frame 069582/0756 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2024
From: EIGER III SA LLC
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 067963/0094 →
SECURITY INTEREST Recorded Jun 28, 2019
From: ESPERION THERAPEUTICS, INC.
To: EIGER III SA LLC, AS PURCHASER AGENT
Reel/Frame 049623/0629 →
MERGER Recorded Oct 14, 2014
From: ESPERION THERAPEUTICS, INC.
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 033946/0330 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2004
From: DASSEUX, JEAN-LOUIS HENRI; ONICIU, CARMEN DANIELA
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 015945/0158 →
Continuity (2)
Provisional Application 6044179500 · Jan 23, 2003
Related Publication 20050043278A1 · Feb 24, 2005